RM-MET / Metabolic and incretin signalling
VK2735
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
VK2735 is an investigational GIP/GLP-1 receptor dual agonist in both injectable and oral development programs.
Evidence position
Published randomized phase 2 subcutaneous results support Grade B. Oral and injectable programs must not be treated as automatically equivalent.
What the record does not establish
The study record does not authenticate a separately sourced material or prove its sequence, modification, route-specific formulation, strength or stability.
Sources
- 01VK2735 VENTURE phase 2 studyClinicalTrials.gov
- Shows
- Official study design, intervention, aliases and completion record
- Does not show
- Registration does not establish approval or lot quality
- 02Weekly subcutaneous VK2735 randomized phase 2 trialPubMed
- Shows
- Published human phase 2 safety and weight-management results
- Does not show
- Short-duration sponsor-involved trial; not evidence about outside material
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBMED / FOUND RECORDS
- Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study.Obesity (Silver Spring, Md.) / 2026 MarPMID 41508550 / DOI 10.1002/oby.70106
CLINICALTRIALS.GOV / FOUND RECORDS
- VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)ACTIVE_NOT_RECRUITING / PHASE3 / Viking Therapeutics, Inc.NCT07104383 / DIRECT intervention MATCH: VK2735
- VK2735 for Weight Management Phase 2COMPLETED / PHASE2 / Viking Therapeutics, Inc.NCT06068946 / DIRECT intervention MATCH: VK2735
- Phase 1 Study to Evaluate the Safety and Tolerability of VK2735COMPLETED / PHASE1 / Viking Therapeutics, Inc.NCT05203237 / DIRECT intervention MATCH: VK2735
- VK2735 for Weight Management Phase 2 (Venture Oral Dosing)COMPLETED / PHASE2 / Viking Therapeutics, Inc.NCT06828055 / DIRECT intervention MATCH: VK2735
- VK2735 for Weight Management Phase 3ACTIVE_NOT_RECRUITING / PHASE3 / Viking Therapeutics, Inc.NCT07104500 / DIRECT intervention MATCH: VK2735